What the research found
Eli Lilly's TRIUMPH-3 trial tested retatrutide (a GLP-1/GIP/glucagon receptor agonist) in obese patients with established cardiovascular disease—the highest-risk population for adverse cardiac events. Participants received placebo, 4 mg/week, 9 mg/week, or 12 mg/week of retatrutide over the trial period.
The headline finding: major adverse cardiovascular events (MACE—defined as all-cause death, myocardial infarction, stroke, heart failure, or coronary revascularization) occurred in 44 participants on the higher retatrutide doses versus 52 on placebo, yielding a hazard ratio of 0.82. This represents an approximate 18% lower event rate, though the confidence interval (0.55–1.22) crosses 1.0, meaning the difference is not statistically significant.
Beyond MACE, the highest dose produced substantial reductions in several cardiovascular risk factors: triglycerides fell by 37%, non-HDL cholesterol by 16.5%, systolic blood pressure by 9.3 mmHg, high-sensitivity C-reactive protein by 51.2%, and waist circumference by 7.5 cm. These improvements occurred despite a known side effect of retatrutide—an increase in resting heart rate—which did not translate into harm in this high-risk cohort.
Why it matters for you
If you're considering retatrutide for body composition or metabolic health, TRIUMPH-3 provides reassurance on a legitimate concern: does the elevated resting heart rate offset benefits elsewhere? The trial's focus on patients with prior cardiac events—the group most vulnerable to adverse outcomes—suggests the magnitude of improvement in triglycerides, blood pressure, inflammation (hsCRP), and weight outweighs the chronotropic effect.
For those tracking biomarkers, this reinforces that GLP-1/GIP/glucagon combinations may deliver steeper drops in triglycerides and inflammatory markers than dual agonists alone. If you monitor heart rate variability, resting heart rate, or blood pressure as part of your protocol, you should expect an upward shift in RHR but potential downward shifts in systolic BP and inflammatory indices.
The caveat: TRIUMPH-3 did not detect a statistically significant reduction in hard cardiovascular events. The trend was favourable, but confidence intervals were wide. This is a Phase 3 safety trial in a specific population (obese + existing CVD), not a definitive proof that retatrutide prevents future events in all users.
Caveats
- Non-significant primary outcome: The 18% reduction in MACE fell within the 95% CI; the trial did not achieve statistical significance for this endpoint.
- High-risk population only: Results apply to obese patients with established cardiovascular disease; generalizability to healthier, younger, or leaner users is unclear.
- Intermediate biomarkers vs. hard endpoints: Improvements in triglycerides, hsCRP, and blood pressure are surrogate markers; the study was not powered to prove they prevent future events.
- Short-term data: TRIUMPH-3 duration is not specified in the excerpt; longer-term safety or efficacy data may differ.
- Resting heart rate concerns unresolved: The mechanism driving elevated RHR and its long-term significance remain incompletely understood, despite the reassuring MACE findings.